Catalyst Pharmaceutical Partners Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.09
  • 50 Day Moving Average: $0.80
  • 200 Day Moving Average: $0.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.89
  • P/E Growth: 0.00
  • Market Cap: $90.33M
  • Outstanding Shares: 82,870,000
  • Beta: 1.14
Additional Links:
Companies Related to Catalyst Pharmaceutical Partners:

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceutical Partners (NASDAQ:CPRX) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $3.42 (213.46% upside)

Analysts' Ratings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetDetails
6/14/2016HC WainwrightReiterated RatingBuyView Rating Details
4/26/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$6.00 -> $1.00View Rating Details
3/22/2016Roth CapitalReiterated RatingBuyView Rating Details
2/20/2016SunTrust Banks Inc.Reiterated RatingBuy$7.00 -> $6.00View Rating Details
6/24/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details
10/1/2014AegisBoost Price TargetPositive$7.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.05)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.09)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.07)($0.05)ViewN/AView Earnings Details
5/16/2014Q114($0.06)($0.07)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Current Year EPS Consensus Estimate: $-0.25 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.06)($0.06)($0.06)
Q2 20161($0.06)($0.06)($0.06)
Q3 20162($0.06)($0.06)($0.06)
Q4 20162($0.08)($0.07)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
DateHeadline
finance.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Financials (NASDAQ:CPRX)
finance.yahoo.com - August 19 at 3:28 PM
News IconCrowd & Street Monitoring Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Post News (NASDAQ:CPRX)
www.kentuckypostnews.com - August 19 at 10:32 AM
finance.yahoo.com logoCatalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3% (NASDAQ:CPRX)
finance.yahoo.com - August 18 at 10:24 AM
finance.yahoo.com logoCatalyst (CPRX) Reports Narrower-than-Expected Q2 Loss (NASDAQ:CPRX)
finance.yahoo.com - August 10 at 4:27 PM
sg.finance.yahoo.com logoCatalyst reports 2Q loss (NASDAQ:CPRX)
sg.finance.yahoo.com - August 10 at 8:04 AM
publicnow.com logoCatalyst Pharmaceuticals Announces Second Quarter 2016 Financial Results and Provides Product Development Update (NASDAQ:CPRX)
www.publicnow.com - August 9 at 5:22 PM
biz.yahoo.com logoQ2 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:CPRX)
biz.yahoo.com - August 9 at 10:51 AM
ftsenews.co.uk logoCatalyst Pharmaceutical Partners, Inc. (CPRX) Updated Price Targets - FTSE News (NASDAQ:CPRX)
www.ftsenews.co.uk - August 5 at 9:42 PM
finance.yahoo.com logoCatalyst (CPRX) Q2 Earnings: Can the Stock Pull a Surprise? (NASDAQ:CPRX)
finance.yahoo.com - August 3 at 10:01 PM
publicnow.com logoCatalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 10th, 2016 (NASDAQ:CPRX)
www.publicnow.com - August 1 at 8:31 AM
ftsenews.co.uk logoNew Broker Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - FTSE News (NASDAQ:CPRX)
www.ftsenews.co.uk - July 15 at 8:27 PM
News IconCrowd Rating and Earnings Recap for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Telanagana Press (NASDAQ:CPRX)
telanaganapress.com - July 15 at 10:03 AM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:CPRX)
telanaganapress.com - July 14 at 8:40 AM
insidermonkey.com logoNoteworthy Insider Transactions at 5 Companies Amid Slowing Insider Buying as Markets Near All-Time Highs (NASDAQ:CPRX)
www.insidermonkey.com - July 13 at 12:35 PM
News Icon2016 Q1 Sentiment Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) - Consumer Eagle (NASDAQ:CPRX)
www.consumereagle.com - July 12 at 9:48 PM
News IconTrading Performance and Target Watch for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph (NASDAQ:CPRX)
presstelegraph.com - July 12 at 8:41 AM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CPRX)
www.engelwooddaily.com - July 12 at 8:41 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX)
www.fiscalstandard.com - July 12 at 8:41 AM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:CPRX)
telanaganapress.com - July 7 at 9:37 PM
fiscalstandard.com logoBroker Outlook For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX)
www.fiscalstandard.com - July 7 at 9:37 PM
News IconStock Rating Watch and Earnings Insight for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph (NASDAQ:CPRX)
presstelegraph.com - July 6 at 9:06 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX)
www.fiscalstandard.com - July 6 at 9:06 AM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Company Rating and Target Watch - Telanagana Press (NASDAQ:CPRX)
telanaganapress.com - June 30 at 11:34 AM
fiscalstandard.com logoRecently Issued Stock Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard (NASDAQ:CPRX)
www.fiscalstandard.com - June 30 at 11:34 AM
News IconShare Update and Earnings Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph (NASDAQ:CPRX)
presstelegraph.com - June 29 at 11:40 AM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:CPRX)
www.engelwooddaily.com - June 28 at 9:16 AM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an (NASDAQ:CPRX)
biz.yahoo.com - June 24 at 5:02 PM
investornewswire.com logoCan Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Surprise Analysts this Quarter? - Investor Newswire (NASDAQ:CPRX)
www.investornewswire.com - June 23 at 3:44 PM
fiscalstandard.com logoCatalyst Pharmaceutical Partners, Inc. (CPRX) Current Analyst Ratings - Fiscal Standard (NASDAQ:CPRX)
www.fiscalstandard.com - June 22 at 4:32 PM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule (NASDAQ:CPRX)
biz.yahoo.com - June 10 at 5:02 PM
capitalcube.com logoCatalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 (NASDAQ:CPRX)
www.capitalcube.com - June 10 at 5:02 PM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters t (NASDAQ:CPRX)
biz.yahoo.com - June 7 at 4:49 PM
News IconAfter Last Week What Do Analysts Think Of Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News (NASDAQ:CPRX)
www.sharetrading.news - June 5 at 9:41 PM
News IconCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update & Estimates - Stock Tick Tock (NASDAQ:CPRX)
www.stockticktock.com - June 4 at 9:43 PM
investornewswire.com logoStrong Sell Calls Count For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 0 - Investor Newswire (NASDAQ:CPRX)
www.investornewswire.com - June 2 at 10:22 PM
News IconStock Review and Earnings Check on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - HNN (NASDAQ:CPRX)
hintsnewsnetwork.com - June 1 at 12:34 PM
News IconCatalyst Pharmaceutical Partners, Inc. (CPRX) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:CPRX)
www.sharetrading.news - May 30 at 1:34 PM
News IconEarnings Review and Stock Rundown for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News (NASDAQ:CPRX)
hintsnewsnetwork.com - May 25 at 12:21 PM
News IconStock Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News (NASDAQ:CPRX)
hintsnewsnetwork.com - May 23 at 2:27 PM
News IconShare Recap and Earnings Focus on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News (NASDAQ:CPRX)
hintsnewsnetwork.com - May 18 at 1:00 PM
publicnow.com logoCatalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve (NASDAQ:CPRX)
www.publicnow.com - May 18 at 9:52 AM
finance.yahoo.com logoCatalyst (CPRX) Resorts to Layoffs for Firdapse Development (NASDAQ:CPRX)
finance.yahoo.com - May 18 at 9:22 AM
finance.yahoo.com logoCatalyst Pharmaceutical’s Firdapse Phase 3 Study Published in Muscle & Nerve (NASDAQ:CPRX)
finance.yahoo.com - May 18 at 8:03 AM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial (NASDAQ:CPRX)
biz.yahoo.com - May 17 at 5:20 PM
publicnow.com logoCatalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan (NASDAQ:CPRX)
www.publicnow.com - May 17 at 8:42 AM
News IconConsensus Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News (NASDAQ:CPRX)
hintsnewsnetwork.com - May 16 at 2:49 PM
stocksdaily.net logoCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) One-Year Mean Price Target At $5.25 - Stocks Daily (NASDAQ:CPRX)
www.stocksdaily.net - May 15 at 6:38 AM
finance.yahoo.com logoCatalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus (NASDAQ:CPRX)
finance.yahoo.com - May 11 at 3:29 PM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CPRX)
biz.yahoo.com - May 10 at 5:47 PM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CPRX)
biz.yahoo.com - May 10 at 4:51 PM

Social

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff